Non-colorectal Liver MetastasisREMENOCORNCT07180641
National Registry of Hepatic Metastases From Non-Colorectal Cancer"
An observational study of Non-colorectal Liver Metastasis and Liver Metastasis, run by Clinica Universidad de Navarra, Universidad de Navarra.
Trial summary
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing a series of recommendations for the treatment of liver metastases from various… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-colorectal Liver Metastasis, Liver Metastasis, Non-neuroendocrine Liver Metastasis
- How many people
- 1,039 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2010to 31 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients scheduled for liver surgery due to non-colorectal liver metastases, regardless of the primary tumor origin, via open or minimally invasive approach, from January 2010 to December 2022
Who may be able to join
- Patients scheduled for liver surgery due to non-colorectal liver metastases, regardless of the primary tumor origin, via open or minimally invasive approach
Who cannot join
- Patients undergoing surgery for colorectal liver metastases, emergency surgical interventions and patients younger than 18 years old.
About this study
Official title: REGISTRO NACIONAL DE METÁSTASIS HEPÁTICAS DE CÁNCER NO COLORRECTAL
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing a series of recommendations for the treatment of liver metastases from various extrahepatic primary tumors
- Conditions
- Non-colorectal Liver Metastasis, Liver Metastasis, Non-neuroendocrine Liver Metastasis, Liver Metastases, Non-colorectal Liver Metastases, Non-neuroendocrine Liver Metastases
- Keywords
- Non-colorectal non-neuroendocrine liver metastases, Liver metastases, Liver resection, Hepatectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with non-colorectal liver metastases | Patients who underwent liver resection for non-colorectal liver metastases from January 2010 to December 2022 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Time from the date of liver resection for non-colorectal metastases to death from any cause. Survival will be assessed for up to 5 years postoperatively
Measured: 5 years from liver resection
Progression-Free Survival
Time from the date of liver resection for non-colorectal metastases to the date of documented disease progression or death from any cause, whichever occurs first. Patients without progression or death will be censored at the last follow-up
Measured: 5 years from surgery
Secondary outcomes (5)
Postoperative Morbidity Rate
Incidence of any postoperative complications occurring within 90 days after liver resection, including but not limited to infections, bleeding, bile leaks, and other surgical complications, classified according to standard criteria.
Measured: 90 days from surgery
Postoperative Mortality Rate
Proportion of patients who die from any cause within 90 days following liver resection surgery.
Measured: 90 days from surgery
Recurrence Pattern
Distribution and characterization of tumor recurrence (hepatic, extrahepatic, or both) after liver resection for non-colorectal metastases.
Measured: Up to 5 years from liver resection
Length of hospital stay
Number of days from surgery to discharge following liver resection
Measured: Perioperative/Periprocedural
R0 Resection Rate
Proportion of patients achieving complete microscopic liver tumor resection (R0) during liver resection
Measured: At surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2025
- Study start1 Jan 2010
- Primary completion31 Dec 2022
- Study completion31 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-colorectal Liver MetastasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,039 participants (actual)
Sponsor and investigators
- Lead sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07180641
- Sponsor's protocol ID
- 2023.238
- Acronym
- REMENOCOR
- Status last verified
- Sep 2025
- First submitted
- 25 Aug 2025
- Last updated
- 18 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be shared with all investigators who have participated in this multicenter study and who have expressed interest in its follow-up and execution. The data will be shared anonymously, as each patient is assigned a unique anonymized identification number unrelated to their clinical records. Access to the data will be available for a period of five years following the end of recruitment, which was June 2025. There is no official repository; interested investigators must contact me directly, and I will provide them with unique and private access to the data
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REGISTRO NACIONAL DE METÁSTASIS HEPÁTICAS DE CÁNCER NO COLORRECTAL
- ClinicalTrials.gov ID
- NCT07180641
- Acronym / sponsor ID
- REMENOCOR / 2023.238
- Conditions
- Non-colorectal Liver Metastasis, Liver Metastasis, Non-neuroendocrine Liver Metastasis, Liver Metastases, Non-colorectal Liver Metastases, Non-neuroendocrine Liver Metastases
- Keywords
- Non-colorectal non-neuroendocrine liver metastases, Liver metastases, Liver resection, Hepatectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,039 participants (actual)
- Lead sponsor
- Clinica Universidad de Navarra, Universidad de NavarraUniversity, hospital or other
- Study start
- 1 Jan 2010 (actual)
- Primary completion
- 31 Dec 2022 (actual)
- Study completion
- 31 Dec 2022 (actual)
- First posted
- 18 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing a series of recommendations for the treatment of liver metastases from various extrahepatic primary tumors
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with non-colorectal liver metastases | – | –Patients who underwent liver resection for non-colorectal liver metastases from January 2010 to December 2022 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients scheduled for liver surgery due to non-colorectal liver metastases, regardless of the primary tumor origin, via open or minimally invasive approach, from January 2010 to December 2022
Key inclusion criteria (1 listed)
- Patients scheduled for liver surgery due to non-colorectal liver metastases, regardless of the primary tumor origin, via open or minimally invasive approach
Key exclusion criteria (1 listed)
- Patients undergoing surgery for colorectal liver metastases, emergency surgical interventions and patients younger than 18 years old.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival
Time frame: 5 years from liver resection
Time from the date of liver resection for non-colorectal metastases to death from any cause. Survival will be assessed for up to 5 years postoperatively
Progression-Free Survival
Time frame: 5 years from surgery
Time from the date of liver resection for non-colorectal metastases to the date of documented disease progression or death from any cause, whichever occurs first. Patients without progression or death will be censored at the last follow-up
5 secondary outcomes
Postoperative Morbidity Rate
Time frame: 90 days from surgery
Postoperative Mortality Rate
Time frame: 90 days from surgery
Recurrence Pattern
Time frame: Up to 5 years from liver resection
Length of hospital stay
Time frame: Perioperative/Periprocedural
R0 Resection Rate
Time frame: At surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Individual participant dataSharing planned: Yes. The data will be shared with all investigators who have participated in this multicenter study and who have expressed interest in its follow-up and execution. The data will be shared anonymously, as each patient is assigned a unique anonymized identification number unrelated to their clinical records. Access to the data will be available for a period of five years following the end of recruitment, which was June 2025. There is no official repository; interested investigators must contact me directly, and I will provide them with unique and private access to the data
Related trials for Non-colorectal Liver Metastasis
RecruitingPhase 1/2
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
RecruitingPhase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Advanced Solid Tumor, Advanced Cancer
Recruiting
TheraSphere Japan Pre-Market Study
Liver Neoplasms
Not yet recruitingPhase 2
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Liver Metastases, Non-Small Cell Lung Cancer
Not yet recruitingObservational study
Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases
Liver Metastases, Liver Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-colorectal Liver Metastasis and Liver Metastasis, run by Clinica Universidad de Navarra, Universidad de Navarra.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 5 years from liver resection). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025; AzTrials last refreshed its copy on 8 Nov 2026.